Tom Marino might have withdrawn from consideration as Trumps drug czar, but narcotic money is coursing through the veins of Congress contributing directly to an epidemic that kills thousands of Americans each year
Donald Trump was not incorrect. Hours before his nominee for” narcotic czar” withdrew from consideration over his part in a law limiting the Drug Enforcement Administration’s ability to crack down on pharmaceutical distributors feeding the US’s opioid epidemic, the president took a shot at the influence of narcotic companies over Congress.
” They contribute massive amounts of fund to political people ,” he said, standing next to Mitch McConnell, the Senate majority leader.
” I don’t know, Mitch, maybe even to you ,” he added.
Trump was right on both countings. Pharmaceutical companies expend far more than any other industry to influence legislators. Drugmakers have poured close to $2.5 bn into lobbying and funding each member of Congress over the past decade.
Hundreds of thousands of dollars have gone to McConnell- although he is hardly alone. Nine out of 10 members of the House of Representative and all but three of the US’s 100 senators have taken campaign contributions from pharmaceutical companies seeking to affect legislation on everything from the cost of drugs to how new medications are approved.
Trump’s nominee for medication czar, the US congressman Tom Marino, was forced to withdraw after a report by the Washington Post and CBS’s 60 Minutes highlighted his role in forging legislation that hinders the DEA’s ability to move against narcotic distributors or pharmacies recklessly dispensing the opioid painkillers at the heart of the epidemic, which claims more than 100 lives a day.
Marino’s acceptance of substantial donations from those same companies compromised his nomination to head the federal agency charged with tackling the opioid crisis.
But for Congress, the process was nothing unusual. Hundreds of millions of dollars flow to lobbyists and politicians on Capitol hill each year to shape laws and policies that keep medication company gains growing. The pharmaceutical industry, which has about two lobbyists for every member of Congress, expended $152 m on influencing legislation in 2016, according to the Center for Responsive Politics. Drug companies also contributed more than $20 m immediately to political campaigns last year. About 60% went to Republican. Paul Ryan, the speaker of the House of Representative, was the single most important beneficiary, with donations from the industry totaling $228,670.
The impact of so much drug company money coursing through the veins of Congress is often incremental or largely unseen by the American public, such as the industry’s efforts to block competitors in India from making generic versions of HIV/ Aids medications that are more affordable to developing countries.
But on occasion it has a hugely visible impact.
In his comments alongside McConnell, Trump was vocal in his criticism of what he said were pharmaceutical manufacturers” get away with assassination” by charging much higher costs in the US than other countries. That is the result of a 2003 law, in effect written by the industry, preventing the federal government from trying bids for the manufacture of drugs and medical devices- a process used in other areas, such as defence spending.
Instead, the pharmaceutical companies can charge whatever cost they want for drugs bought for the publicly run Medicare and Medicaid programmes- and the federal government has no choice but to pay up.
Read more: www.theguardian.com